PT-302(Phanes Therapeutics)

N/A

Report date: 2022/08/26 10:54:22

Base Information

Drug NamePT-302(Phanes Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Hepatitis A virus cellular receptor 2Lymphocyte activation gene 3 protein inhibitors

TargetsHepatitis A virus cellular receptor 2Lymphocyte activation gene 3 protein

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPhanes Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPhanes Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A